All SPaL regimen articles
-
NewsPhase 2 clinical trial results show potential to shorten TB treatment time
New clinical trial results show that the novel antibiotic candidate sorfequiline (TBAJ-876), a next-generation diarylquinoline, has the potential to improve tuberculosis (TB) treatment when combined with pretomanid and linezolid in a treatment regimen known as “SPaL.”